Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
Contract research and manufacturing organization Albany Molecular Research has made George Svokos chief operating officer, and Lori Henderson head of corporate business development. 14 September 2015
EMD Serono, the biopharma division of German pharma company Merck, has appointed Scott Filosi as senior vice president of managed markets. 10 September 2015
Autifony Therapeutics, a UK-based biotech company specializing in hearing loss and tinnitus, has appointed John Hutchison as chief medical officer. 3 September 2015
ACADIA Pharmaceuticals has submitted a New Drug Application to the US Food and Drug Administration seeking approval for Nuplazid (pimavanserin) for the treatment of psychosis associated with Parkinson’s disease. 3 September 2015
Anglo-Swedish drug major AstraZeneca has appointed Sean Bohen as executive vice president of global medicines development and chief medical officer. 24 August 2015
Germany’s Merck KGaA named Isabel De Paoli head of group communications effective March 9, 2016. She will succeed Walter Huber, who is set to retire in March next year. 30 July 2015
Pharma giant Merck & Co on Tuesday said it has agreed to buy Israel-based drugmaker cCAM Biotherapeutics for as much as $605 million in a bid to expand its immuno-oncology portfolio. 29 July 2015
US biotech major Gilead Sciences on Tuesday named William Lee the executive vice president (EVP) for research, and Brett Pletcher the EVP and general counsel. Both Mr Lee and Mr Pletcher will join the company’s senior leadership committee. 28 July 2015
Privately-held pharma company Otic, focused on ear, nose and throat disorders, has appointed Gregory Flesher as chief executive and member of the board. 27 July 2015
Synthetic biology specialist Intrexon Corp has appointed Jack Bobo as senior vice president, chief communications officer, Samuel Broder as senior vice president, head of health, and Joel Liffman as senior vice president, finance. 22 July 2015